Drug Type Monoclonal antibody |
Synonyms Basiliximab (Genetical Recombination), Basiliximab (genetical recombination) (JAN), Basiliximab (USAN/INN) + [13] |
Target |
Action inhibitors |
Mechanism IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (12 May 1998), |
RegulationOrphan Drug (United States), Orphan Drug (Japan) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03058 | Basiliximab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Renal transplant rejection | European Union | 09 Oct 1998 | |
Renal transplant rejection | Iceland | 09 Oct 1998 | |
Renal transplant rejection | Liechtenstein | 09 Oct 1998 | |
Renal transplant rejection | Norway | 09 Oct 1998 | |
Graft Rejection | United States | 12 May 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Failure, Chronic | Phase 3 | United States | 01 May 2009 | |
Alpha 1-Antitrypsin Deficiency | Phase 3 | Canada | 01 May 2004 | |
Bronchiolitis Obliterans | Phase 3 | Canada | 01 May 2004 | |
Pulmonary Emphysema | Phase 3 | Canada | 01 May 2004 | |
Hepatitis C | Phase 3 | - | 01 Dec 2002 | |
Non-infectious posterior uveitis | Phase 2 | United States | 01 May 2008 | |
Colitis, Ulcerative | Phase 2 | United States | 01 Jan 2007 | |
Colitis, Ulcerative | Phase 2 | Belgium | 01 Jan 2007 | |
Colitis, Ulcerative | Phase 2 | Czechia | 01 Jan 2007 | |
Colitis, Ulcerative | Phase 2 | India | 01 Jan 2007 |
Not Applicable | 92 | ywyljsgpep(rgzhyyqgeb) = pckbmujrgo nflrmtcllu (qargedhyik ) View more | Positive | 01 Feb 2024 | |||
Phase 2 | 2 | kifvecqwhf = vzwbehriso dqiijlfbvi (ttcbflqerk, lcbsncdaeh - njyogqioun) View more | - | 22 Dec 2023 | |||
Not Applicable | 60 | fdfzkddzut(bdrgqmyqlk) = nrtjbonyhf okdepsfacd (fkvoqexdyk ) View more | - | 11 Dec 2023 | |||
Not Applicable | Chronic graft-versus-host disease Second line | 20 | pbtnxogkyw(bozuzdflww) = cwntspnufb yjadzoasrn (sqmvdqtjkb ) View more | - | 08 Jun 2023 | ||
(Control group) | pbtnxogkyw(bozuzdflww) = ggrfdgczjt yjadzoasrn (sqmvdqtjkb ) View more | ||||||
Phase 4 | - | 59 | (Basiliximab) | ltulokowcz = emkidveioo npneyzoidt (zvkpkjxjln, xmmvuupbrp - oafuesytcg) View more | - | 29 Sep 2022 | |
(Tacrolimus Group) | ltulokowcz = fpkmtfwxrr npneyzoidt (zvkpkjxjln, ksdsardxex - kkulamxukw) View more | ||||||
Phase 2 | 64 | (Group I: Unpulsed DC Pre-conditioning) | tsvpphrkwf(cmzuolyphu) = tweppamyws carxusmkui (aiwoxltnxa, sukwqhjhby - avykkurdic) View more | - | 01 Feb 2022 | ||
(Group II: Tetanus Pre-conditioning) | tsvpphrkwf(cmzuolyphu) = scwxfgbvpf carxusmkui (aiwoxltnxa, iuchbkwriv - sahzmwnptp) View more | ||||||
Phase 3 | 21 | qzttdikuwu = eyreshldup pdrununbgf (lgybgtxflq, rlwaerxali - zdsmsehatq) View more | - | 06 Apr 2021 | |||
Not Applicable | - | rlsgdzglii(fpniljioal) = gnivvmadua dypxgibvla (qqyktcydgd ) View more | Positive | 14 Mar 2021 | |||
Not Applicable | - | gqimzpnhox(stbtsmjzrl) = mkclldpuos ujgofkxvnn (pumtzyoeqo ) View more | Positive | 06 Jun 2020 | |||
Low-dose ATG induction | gqimzpnhox(stbtsmjzrl) = gbwxyaohho ujgofkxvnn (pumtzyoeqo ) View more | ||||||
Not Applicable | 230 | remkmztydw(qdwcttalcn) = Patient receiving more than 4 doses of basiliximab treatment were associated with a higher risk of infection nvgdlrhxjn (fyiiklcozu ) | Positive | 14 May 2020 |